3 Likes
Thanks. This year I ordered OneTest for the reason stated. At my appointment with my GP next year I will inquire about Galleri and see if an age exception can be made as you suggested.
Comparing the different tests, I do not believe there is a “best option” for everyone. What is being tested varies as does the specificity and sensitivity of the output. For me that means there may be some advantages of taking multiple cancer blood tests.
1 Like
Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation
MCED is able to detect multiple cancer types by analyzing cfDNAs, cfRNAs, circulating proteins and metabolites using liquid-based biopsy techniques and AI algorithms. The TOO results of an MCED test provide further guidance for subsequent clinical diagnosis and treatment. This new screening paradigm will eventually reduce cancer-specific mortality and be recommended for a broader population.
Liquid biopsy-based multi-cancer early detection (MCED) is regarded as a breakthrough in cancer screening and prevention. With advantages such as broad population and cancer-type coverage, minimal invasiveness, high patient compliance, and favorable health economic outcomes, MCED enables the detection of multiple cancers simultaneously—potentially with tissue-of-origin localization—through the analysis of biological markers such as cfDNA, cfRNA, and proteins collected from blood or other body fluids, enhanced by AI-driven algorithms.
Although several products have advanced their MCED platforms through technical development and into clinical phases, no MCED product has yet been approved for market release globally. This indicates that the translational pathway from laboratory research to clinical implementation still requires further validation through clinical trials and real-world evidence. From the standpoint of clinical efficacy, key metrics such as sensitivity, specificity, and TOO accuracy serve as crucial evidentiary endpoints and merit in-depth investigation. From the clinical utility perspective, “reduction in late-stage cancer incidence” is increasingly recognized as a feasible and credible surrogate endpoint for “reduction in cancer-specific mortality,” given its shorter time span, lower cost, and higher practicality. Policymakers in public health must weigh a wide range of clinical evidence carefully when developing MCED-related screening guidelines.
At present, MCED should be viewed as a complementary, rather than replacement, strategy to existing cancer screening modalities.